title: A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
abstract: We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.
authors.affiliation: Division of Hematology, Mayo Clinic College of Medicine, 200 First St. S.W., Rochester, MN 55905, USA. litzow.mark@mayo.edu
authors.forename: Mark R
authors.initials: MR
authors.lastname: Litzow
authors.forename: Sandra
authors.initials: S
authors.lastname: Lee
authors.forename: John M
authors.initials: JM
authors.lastname: Bennett
authors.forename: Gordon W
authors.initials: GW
authors.lastname: Dewald
authors.forename: Robert E
authors.initials: RE
authors.lastname: Gallagher
authors.forename: Vibha
authors.initials: V
authors.lastname: Jain
authors.forename: Elisabeth M
authors.initials: EM
authors.lastname: Paietta
authors.forename: Janis
authors.initials: J
authors.lastname: Racevskis
authors.forename: Steven R
authors.initials: SR
authors.lastname: Rousey
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Mazza
authors.forename: Martin S
authors.initials: MS
authors.lastname: Tallman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D006801:Humans; D010087:Oxides / Q000627:therapeutic use* / Q000633:toxicity; D018579:Patient Selection; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide